| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351691 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US7208471 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US6635618 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Sep, 2023
(7 months ago) | |
| US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101575 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US7700550 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US7544364 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(2 years ago) | |
| US8158580 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(2 years ago) | |
| US7008923 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US6872701 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Jun, 2021
(2 years ago) | |
| US6858584 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(1 year, 8 months ago) | |
Vibativ is owned by Cumberland.
Vibativ contains Telavancin Hydrochloride.
Vibativ has a total of 11 drug patents out of which 10 drug patents have expired.
Expired drug patents of Vibativ are:
- US8101575
- US7700550
- US7544364
- US8158580
- US7008923
- US6872701
- US6858584
- US7351691
- US7208471
- US6635618
Vibativ was authorised for market use on 11 September, 2009.
Vibativ is available in powder;intravenous dosage forms.
Vibativ can be used as method of treating a staphylococcal infection, method of treating bacterial infections, method for treating bacterial infection.
Drug patent challenges can be filed against Vibativ from 11 September, 2013.
The generics of Vibativ are possible to be released after 01 January, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-673) | Jun 21, 2016 |
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Treatment: Method of treating bacterial infections; Method of treating a staphylococcal infection; Method for treating bacterial infection
Dosage: POWDER;INTRAVENOUS
VIBATIV family patents
